Subtype
Female Reproductive System Carcinoma
CI-CAN-00002685Explore in graph →
458 active trials5 approved drugs36 evidence items
- NCIt
- C181162
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002685Explore in graph →
Clinical trials
1,481 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00023712 | Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01305213 | Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | completed | Phase 2 | 107 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 |
| clinicaltrials |
| NCT00022659 | Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00025155 | Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00025233 | Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00053365 | Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00095979 | Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00096447 | Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00113373 | Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00301964 | Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00429793 | Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00093626 | Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00132067 | Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00416455 | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer | completed | Phase 1 / Phase 2 | 384 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT00462826 | VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00723255 | Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00729586 | Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00993616 | Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01011933 | Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01468909 | Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | completed | Phase 2 | 106 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01540565 | Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT03836157 | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | withdrawn | Phase 2 | 0 | University of OklahomaOTHER | 1 | Jun 27, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT02575807 | Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer(SEASCAPE) | terminated | Phase 1 / Phase 2 | 35 | Aduro Biotech, Inc.INDUSTRY | 2 | Apr 4, 2019 | clinicaltrials |
| NCT01267253 | Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Mar 20, 2019 | clinicaltrials |
| NCT02948101 | PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT01381861 | Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | completed | Phase 2 | 23 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT00436501 | VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Feb 26, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT00939809 | A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Jan 15, 2019 | clinicaltrials |
| NCT00309959 | ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT02868892 | A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas | terminated | Phase 2 | 6 | Western Regional Medical CenterOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2018 | clinicaltrials |
| NCT01037049 | Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks | unknown | Phase 2 | 237 | Royal Marsden NHS Foundation TrustOTHER | 4 | Sep 17, 2018 | clinicaltrials |
| NCT00278343 | Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 2 | Aug 29, 2018 | clinicaltrials |
| NCT00467051 | Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors | completed | Phase 2 | 20 | Children's Oncology GroupNETWORK | 4 | Aug 29, 2018 | clinicaltrials |
| NCT00301756 | Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2018 | clinicaltrials |
| NCT02107950 | Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma | completed | Phase 2 | 71 | SOTIO a.s.INDUSTRY | 3 | Aug 15, 2018 | clinicaltrials |
| NCT03469531 | Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer | unknown | Phase 2 | 100 | Zhujiang HospitalOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT01091428 | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | completed | Phase 2 | 191 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 4, 2018 | clinicaltrials |
| NCT01764802 | Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer | completed | Phase 2 | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT02879214 | Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer(Side) | unknown | Phase 2 | 50 | Sichuan Provincial People's HospitalOTHER | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01773889 | A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer | terminated | Phase 2 | 2 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT00483327 | Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate | completed | Phase 2 | 31 | NYU Langone HealthOTHER | 1 | Apr 4, 2018 | clinicaltrials |
| NCT01653912 | Dose-finding Study in Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 59 | AccentureINDUSTRY | 3 | Apr 2, 2018 | clinicaltrials |
| NCT00880360 | A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer(ONTAK) | completed | Phase 2 | 19 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Mar 27, 2018 | clinicaltrials |
| NCT00369122 | Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 2 | Mar 20, 2018 | clinicaltrials |
| NCT01005329 | Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 3 | Mar 15, 2018 | clinicaltrials |
| NCT01642082 | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 28 | Gynecologic Oncology GroupNETWORK | 1 | Mar 13, 2018 | clinicaltrials |
| NCT01210222 | Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer | completed | Phase 2 | 35 | Gynecologic Oncology GroupNETWORK | 1 | Feb 23, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jul 30, 2019source: clinicaltrials